Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that 2% minoxidil solution was at least as effective as 3% for increasing hair growth and stabilizing bald areas in men with male pattern baldness.

This study suggests that the action of minoxidil in stimulating hair growth likely occurs at the follicular dermal papilla, though it does not induce new follicle formation.

In this study on a murine model, researchers observed that a 5% minoxidil solution reduced stress-induced changes in hair growth, suggesting its potential for managing stress-related hair loss in humans.

This study found that topical application of 2% minoxidil solution was not effective in improving erectile dysfunction in the majority of participants.

This study found that 2% ketoconazole solution stimulated hair growth significantly in a mouse model, suggesting potential benefits for male pattern hair loss.

This study found that cyclophosphamide-induced hair follicle damage in C3H mice could be remodelled into intact anagen hair follicles with topical cyclosporin A, especially in anagen IV stage follicles.

This study found that diphencyprone showed a significant clinical response for treating alopecia areata, while tacrolimus was not effective.

In this study, topical minoxidil was reported to increase fenestration in follicular capillary walls around anagen hair bulbs in male rats.

This study found that topically administered spironolactone in healthy volunteers resulted in no detectable systemic absorption or changes in related hormone levels over 72 hours, indicating local effect only.

This study reports that over 70% of responding dermatologists prescribed topical minoxidil, but a small percentage accounted for most prescriptions and few reported complications beyond local irritation.

This study found that minoxidil pretreatment in rat skin flaps enhanced angiogenesis and increased flap survival compared to untreated flaps, but was less effective at reducing necrosis than surgical delay.

This study suggests that topical finasteride may benefit women with facial hirsutism, based on observations from a small sample.

This study reports that a new topical solution, AB-102, containing a high concentration of a weak α1 agonist, significantly reduces hair shedding during brushing by up to 77% without causing cardiac or hemodynamic adverse events.

This abstract provides no research findings or scientific content; it appears to be a website cookie policy and terms of use statement.

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

This study found that 1% topical minoxidil induced significant hair regrowth in patients with alopecia areata, though it was less effective for those with extensive hair loss such as alopecia totalis and universalis.

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

This study found that combining topical eflornithine with triple diode laser treatments in women with hirsutism led to a more rapid and nearly complete reduction of terminal hair after 6 months, though the intergroup differences were not significant at 6- and 12-month follow-ups.

This study found that topical minoxidil solutions showed the highest skin permeation at 3-4% concentrations, with crystallization occurring at a 5% concentration due to vehicle component evaporation.

This study found that 32% of patients with hereditary male pattern baldness experienced cosmetically acceptable hair growth after applying topical minoxidil twice daily, with no serious side effects reported.

In this study, 3% topical minoxidil showed some efficacy in hair regrowth for patients with extensive alopecia areata, especially those with less than total scalp hair loss, but did not lead to complete remission.

Topical minoxidil is a safe and effective treatment for hair loss caused by androgenetic alopecia.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

This study reported that sulfotransferase activity in plucked hair follicles can predict treatment response to 5% topical minoxidil in women with androgenetic alopecia with high sensitivity and specificity.

This report describes a case where a 4-year-old boy with congenital alopecia due to hypohidrotic ectodermal dysplasia experienced significant hair growth after using topical minoxidil.

Hair enzyme activity predicts minoxidil success in Brazilian women with hair loss.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.

This study found that Polygonum multiflorum extract may promote hair growth by inducing the anagen phase in the resting hair follicles of mice.

In this study, topical CUR61414 was effective in inhibiting basal cell carcinomas in mice, but no clinical activity was observed in human trials.